Clinical Study

Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation

Figure 2

Serum levels of IL-13 in patients with insulin resistance and controls. Systemic levels of IL-13 showed a 2.5-fold significant increase in patients with insulin resistance as compared to noninsulin resistance controls. NIR: noninsulin resistance controls; IR: patients with insulin resistance. A 3.8 cut-off point was used for defining insulin resistance in the study population. Data are expressed as mean ± standard deviation. Differences were considered significant when and calculated using Student’s t-test.